$14.72
+0.18 (+1.20%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where FDMT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 observational
Held by 10 tracked-famous managers (CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Schonfeld Strategic Advisors LLC, TWO SIGMA INVESTMENTS, LP, Man Group plc, +5 more) · FINRA short interest 17.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| 4D-150 in Patients With Diabetic Macular EdemaNCT05930561Incidence and severity of TEAEs and SAEs, including clinically significant changes in safety parameters (Part 1)Non-randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Biological: 4D-150 IVT, Aflibercept IVT | Diabetic Macular Edema, Diabetic Retinopathy | 72 | 2029-02-28 | in 924 d | 2025-09-22 |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT07064759Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Neovascular Age-Related Macular Degeneration (nAMD) | 480 | Nov 2028 | ≤ 834 d | 2026-04-16 |
| 4D-710 in Adult Patients With Cystic FibrosisNCT05248230Incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: 4D-710 | Cystic Fibrosis Lung | 30 | Jun 2027 | ≤ 315 d | 2026-07-06 |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT06864988Mean change from baseline in BCVA ETDRS letter score at Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Macular Neovascularization Secondary to Age-Related Macular Degeneration | 480 | Jun 2027 | ≤ 315 d | 2026-06-01 |
| Dose Escalation Study of Intravitreal 4D-110 in Patients With ChoroideremiaNCT04483440Frequency and severity of ocular and systemic adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: 4D-110 | Choroideremia | 13 | 2027-05-26 | in 280 d | 2025-05-22 |
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationNCT05197270Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parametersRandomized · Single-masked · Treatment | Phase 1/2 | Recruiting | Biological: 4D-150 IVT, Aflibercept IVT | Neovascular (Wet) Age-Related Macular Degeneration | 215 | Mar 2027 | ≤ 224 d | 2026-02-12 |
| 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)NCT04517149Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parametersNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: 4D-125 IVT Injection · Other: Observational | X-Linked Retinitis Pigmentosa | 21 | Jun 2026 | — | 2025-03-21 |
| 4D-310 in Adults With Fabry Disease and Cardiac InvolvementNCT05629559Incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: 4D-310 | Fabry Disease | 18 | Jun 2026 | — | 2025-02-21 |
| An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry DiseaseNCT04519749Incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: 4D-310 | Fabry Disease | 18 | Jan 2026 | — | 2024-04-08 |
| "Natural History" Study of ChoroideremiaNCT02994368observationalRate of progression of disease | — | Terminated | Other: Observation | Choroideremia | 57 | Oct 2021actual | — | 2022-01-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19